



SAFETY DATA SHEET

Revision date: 01-Mar-2015

Version: 3.0

Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Azithromycin Extended Release for Oral Suspension

Trade Name: Zmax; Zithromax; Zetamax; Zitromax; Zetamac; Azitrocin; Zitralval

Synonyms: Azithromycin Sustained Release Oral Powder for Suspension

Chemical Family: Azalide

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Hazard Statements: May form combustible dust concentrations in air

Other Hazards

Australian Hazard Classification (NOHSC):

No data available
Non-Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Additional Information:

For a more detailed discussion of potential health hazards and toxicity see Section 11.

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 2 of 11

Version: 3.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Azithromycin dihydrate	117772-70-0	Not Listed	Not Listed	Not Listed	8.33
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	*
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Spray dried artificial banana flavor	MIXTURE	Not Listed	Not Listed	Not Listed	*
Spray dried artificial cherry flavor	MIXTURE	Not Listed	Not Listed	Not Listed	*
Sodium phosphate tribasic, anhydrous	7601-54-9	231-509-8	Not Listed	Not Listed	*
Glyceryl behenate	18641-57-1	242-471-7	Not Listed	Not Listed	*
Magnesium hydroxide	1309-42-8	215-170-3	Not Listed	Not Listed	*
Poloxamer 407	9003-11-6	Not Listed	Not Listed	Not Listed	*
Xanthan gum	11138-66-2	234-394-2	Not Listed	Not Listed	*
Hydroxypropyl cellulose	9004-64-2	Not Listed	Not Listed	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 3 of 11

Version: 3.0

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Azithromycin dihydrate

Pfizer OEL TWA-8 Hr: 500µg/m³

Sucrose

ACGIH Threshold Limit Value (TWA) 10 mg/m³
Australia TWA 10 mg/m³
Belgium OEL - TWA 10 mg/m³
Bulgaria OEL - TWA 10.0 mg/m³

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 4 of 11

Version: 3.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

Colloidal silicon dioxide

Australia TWA	2 mg/m ³
Austria OEL - MAKs	4 mg/m ³
	0.3 mg/m ³
Czech Republic OEL - TWA	0.1 mg/m ³
	4.0 mg/m ³
Estonia OEL - TWA	2 mg/m ³
Finland OEL - TWA	5 mg/m ³
Germany - TRGS 900 - TWAs	4 mg/m ³
Germany (DFG) - MAK	4 mg/m ³
Ireland OEL - TWAs	6 mg/m ³
	2.4 mg/m ³
Latvia OEL - TWA	1 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
	Listed
Slovakia OEL - TWA	4.0 mg/m ³
Switzerland OEL - TWAs	4 mg/m ³
	0.3 mg/m ³

Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	10 mg/m ³
Austria OEL - MAKs	5 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Denmark OEL - TWA	6 mg/m ³
Estonia OEL - TWA	5 mg/m ³
France OEL - TWA	10 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
Latvia OEL - TWA	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10.0 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Russia OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 5 of 11

Version: 3.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Sweden OEL - TWAs	5 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³
Vietnam OEL - TWAs	6 mg/m ³
	5 mg/m ³

Analytical Method:	Analytical method available for Azithromycin. Contact Pfizer Inc for further information.
Exposure Controls	
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Powder	Color:	White to off-white
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
Solubility:	Soluble: Water
pH:	9.5 - 12.0 (reconstituted) (60 ml)
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	
Water	No data available
Sucrose	No data available
Glyceryl behenate	No data available
Magnesium hydroxide	No data available
Spray dried artificial banana flavor	No data available
Spray dried artificial cherry flavor	No data available
Colloidal silicon dioxide	No data available
Titanium dioxide	No data available
Xanthan gum	

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 6 of 11

Version: 3.0

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available

Hydroxypropyl cellulose

No data available

Poloxamer 407

No data available

Sodium phosphate tribasic, anhydrous

No data available

Azithromycin dihydrate

Measured 7 Log P 0.67

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause eye irritation (based on components) .

Known Clinical Effects: May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain. Serious allergic reactions, including anaphylaxis, have been reported.

Acute Toxicity: (Species, Route, End Point, Dose)

Sucrose

Rat Oral LD50 29.7 g/kg

Glyceryl behenate

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 7 of 11

Version: 3.0

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 5 g/kg

Magnesium hydroxide

Rat Oral LD50 8500 mg/kg

Rat Sub-tenon injection (eye) LD50 2780mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg

Rat Subcutaneous LD50 50 mg/kg

Xanthan gum

Rat Oral LD50 > 5000 mg/kg

Azithromycin dihydrate

Mouse (F) Oral LD50 4000 mg/kg

Mouse (M) Oral LD50 3000mg/kg

Rat Oral LD50 > 2000mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Magnesium hydroxide

Eye Irritation Rabbit Moderate

Azithromycin dihydrate

Antigenicity- Active anaphylaxis Guinea Pig Negative

Antigenicity- Passive cutaneous anaphylaxis Rabbit Negative

Antigenicity- Passive cutaneous anaphylaxis Mouse Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Azithromycin dihydrate

6 Month(s) Rat Oral 10 mg/kg/day LOEL Liver

6 Month(s) Dog Oral 10 mg/kg/day LOEL Liver

1 Month(s) Rat Intravenous 5 mg/kg/day NOEL Liver

1 Month(s) Dog Intravenous 5 mg/kg/day NOEL Liver

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Azithromycin dihydrate

Reproductive & Fertility Rat Oral 10 mg/kg/day NOEL Fertility

Prenatal & Postnatal Development Mouse Oral 40 mg/kg/day NOEL Not Teratogenic

Prenatal & Postnatal Development Rat Oral 40 mg/kg/day NOEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Azithromycin dihydrate

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 8 of 11

Version: 3.0

11. TOXICOLOGICAL INFORMATION

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Cytogenetics Mouse Lymphoma Negative
In Vitro Cytogenetics Mouse Negative
In Vitro Cytogenetics Human Lymphocytes Negative

Carcinogen Status: See below

Colloidal silicon dioxide

IARC: Group 3 (Not Classifiable)

Titanium dioxide

IARC: Group 2B (Possibly Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview: In the environment, the active ingredient in this formulation is expected to mainly reside in the aquatic environment and slowly degrade.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Azithromycin dihydrate

Daphnia magna (Water Flea) OECD EC50 48 Hours 120 mg/L
Hyallolella azteca (Freshwater Amphipod) OECD LC50 96 Hours > 120 mg/L
Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 Hours > 84 mg/L
Green Algae OECD EC50 72 Hours 0.0037 mg/L
Microcystis aeruginosa (Blue-green Alga) OECD ErC50 96 Hours 0.0018 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Azithromycin dihydrate

Aspergillus niger (Fungus) OECD MIC > 1000 mg/L
Trichoderma viride (Fungus) OECD MIC > 1000 mg/L
Clostridium perfringens (Bacterium) OECD MIC 2.0 mg/L
Bacillus subtilis (Bacterium) OECD MIC 2.0 mg/L

Terrestrial Toxicity: (Species, Method, End Point, Duration, Result)

Azithromycin dihydrate

Eisenia foetida (Earthworm) TAD NOEC 28 Days 1000 mg/kg

Azithromycin dihydrate

Pimephales promelas (Fathead Minnow) OECD 32 Day(s) NOEC 4.6 mg/L Survival
Ceriodaphnia dubia (Daphnids) OPPTS 7 Day(s) NOEC 0.0044 mg/L Reproduction

Persistence and Degradability: No data available

Bio-accumulative Potential:

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 9 of 11

Version: 3.0

Partition Coefficient: (Method, pH, Endpoint, Value)

Azithromycin dihydrate

Measured 7 Log P 0.67

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Azithromycin dihydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Spray dried artificial banana flavor

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 10 of 11

Version: 3.0

15. REGULATORY INFORMATION

Spray dried artificial cherry flavor	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Sodium phosphate tribasic, anhydrous	
CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb
California Proposition 65	2270 kg
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Present
	231-509-8
Glyceryl behenate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	242-471-7
Magnesium hydroxide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-170-3
Poloxamer 407	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed
Xanthan gum	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	234-394-2
Sucrose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9
Colloidal silicon dioxide	

SAFETY DATA SHEET

Material Name: Azithromycin Extended Release for Oral
Suspension
Revision date: 01-Mar-2015

Page 11 of 11

Version: 3.0

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-545-4

Hydroxypropyl cellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Titanium dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 9/2/11 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5

Water

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 12 - Ecological Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 01-Mar-2015

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet